title: BRAF and beyond: Tailoring strategies for the individual melanoma patient.
abstract: Until recently, options for therapy in metastatic melanoma were limited. The understanding of immune check-point blockade and the discovery of molecular pathways involving driver mutations like BRAF has transformed the therapeutic landscape in this disease. Ipilimumab was the first drug shown to improve survival while vemurafenib demonstrated rapid responses never seen before in melanoma. Drugs from these classes and others are now in advanced stages of development and primed to positively impact patient survival in an incremental fashion. In this review, we highlight some of the developments during this renaissance in melanoma therapy and discuss agents of promise. Clinical challenges we face include individualizing therapy for patients, overcoming resistance to molecularly targeted therapy and developing rationale combinations or sequences of drugs. A concerted bench and bedside effort in this direction will undoubtedly keep melanoma in the forefront in an era of personalized medicine.
authors.affiliation: Department of Pharmacy, James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, USA.
authors.forename: Anthony
authors.initials: A
authors.lastname: Jarkowski
authors.affiliation: Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA.
authors.forename: Nikhil I
authors.initials: NI
authors.lastname: Khushalani
keywords: BRAF; MEK; immunotherapy; melanoma
references.citation: Nature. 2012 Jul 26;487(7408):500-4
references.pmid: 22763439
references.citation: Pigment Cell Melanoma Res. 2008 Aug;21(4):492-3
references.pmid: 18510589
references.citation: Clin Cancer Res. 2013 Jul 1;19(13):3611-20
references.pmid: 23620404
references.citation: Nature. 2006 Jan 19;439(7074):358-62
references.pmid: 16273091
references.citation: J Immunother. 2012 Jan;35(1):66-72
references.pmid: 22130161
references.citation: Clin Cancer Res. 2008 Nov 1;14(21):6821-8
references.pmid: 18980976
references.citation: J Clin Oncol. 2013 Jan 20;31(3):373-9
references.pmid: 23248256
references.citation: J Clin Oncol. 1999 Jul;17(7):2105-16
references.pmid: 10561265
references.citation: Clin Cancer Res. 2012 Mar 1;18(5):1457-63
references.pmid: 22261812
references.citation: J Biol Chem. 2012 Aug 10;287(33):28087-98
references.pmid: 22730329
references.citation: N Engl J Med. 2010 Aug 26;363(9):809-19
references.pmid: 20818844
references.citation: J Immunol. 1997 Jun 1;158(11):5091-4
references.pmid: 9164923
references.citation: Dermatology. 2010;220(1):77-81
references.pmid: 19996579
references.citation: Immunity. 1995 Nov;3(5):541-7
references.pmid: 7584144
references.citation: N Engl J Med. 2010 Dec 2;363(23):2191-9
references.pmid: 21083380
references.citation: N Engl J Med. 2013 Apr 4;368(14):1365-6
references.pmid: 23550685
references.citation: J Clin Oncol. 2013 Feb 10;31(5):616-22
references.pmid: 23295794
references.citation: Oncologist. 2013;18(3):314-22
references.pmid: 23457002
references.citation: N Engl J Med. 2012 Jul 12;367(2):107-14
references.pmid: 22663011
references.citation: Clin Cancer Res. 2011 Oct 15;17(20):6574-81
references.pmid: 21880788
references.citation: N Engl J Med. 2012 Jun 28;366(26):2455-65
references.pmid: 22658128
references.citation: Clin Cancer Res. 2013 Jan 15;19(2):462-8
references.pmid: 23169436
references.citation: N Engl J Med. 2010 Aug 19;363(8):711-23
references.pmid: 20525992
references.citation: Clin Cancer Res. 2011 Dec 1;17(23):7462-9
references.pmid: 21976544
references.citation: Clin Cancer Res. 2012 Jan 15;18(2):555-67
references.pmid: 22048237
references.citation: Clin Dermatol. 2013 Mar-Apr;31(2):179-90
references.pmid: 23438381
references.citation: Cancer Res. 2010 Mar 15;70(6):2264-73
references.pmid: 20215513
references.citation: Nat Clin Pract Oncol. 2008 Dec;5(12):737-40
references.pmid: 18936790
references.citation: J Clin Oncol. 2013 Feb 1;31(4):482-9
references.pmid: 23248257
references.citation: Br J Cancer. 2006 Sep 4;95(5):581-6
references.pmid: 16880785
references.citation: J Clin Oncol. 2008 May 1;26(13):2139-46
references.pmid: 18390968
references.citation: Nature. 2010 Dec 16;468(7326):973-7
references.pmid: 21107323
references.citation: Cancer Res. 2010 Aug 15;70(16):6670-81
references.pmid: 20647317
references.citation: N Engl J Med. 2012 Jun 28;366(26):2443-54
references.pmid: 22658127
references.citation: J Clin Oncol. 2011 Aug 1;29(22):3085-96
references.pmid: 21383288
references.citation: J Clin Oncol. 2012 Jan 1;30(1):34-41
references.pmid: 22124101
references.citation: Invest New Drugs. 2005 Dec;23(6):569-75
references.pmid: 16034524
references.citation: J Clin Oncol. 2012 Nov 1;30(31):3810-8
references.pmid: 23008300
references.citation: Ann Surg Oncol. 2007 Aug;14(8):2367-76
references.pmid: 17534686
references.citation: Nature. 2011 Nov 23;480(7377):387-90
references.pmid: 22113612
references.citation: N Engl J Med. 2011 Jun 30;364(26):2507-16
references.pmid: 21639808
references.citation: J Immunother. 2011 Jul-Aug;34(6):509-15
references.pmid: 21654521
references.citation: Cancer. 2013 May 1;119(9):1675-82
references.pmid: 23400564
references.citation: Br J Cancer. 2004 Jul 19;91(2):355-8
references.pmid: 15188009
references.citation: Cancer J. 2012 Mar-Apr;18(2):142-7
references.pmid: 22453015
references.citation: Cancer J. 2012 Mar-Apr;18(2):192-202
references.pmid: 22453021
references.citation: Cancer. 2013 Feb 1;119(3):586-92
references.pmid: 22915053
references.citation: Lancet. 2012 May 19;379(9829):1893-901
references.pmid: 22608338
references.citation: Cancer. 2006 May 1;106(9):2005-11
references.pmid: 16565971
references.citation: Cancer Res. 2010 Nov 1;70(21):8736-47
references.pmid: 20959481
references.citation: Clin Cancer Res. 2007 Mar 1;13(5):1576-83
references.pmid: 17332304
references.citation: Br J Cancer. 2008 Sep 2;99(5):734-40
references.pmid: 18728664
references.citation: Cancer Res. 2011 Aug 1;71(15):5067-74
references.pmid: 21803746
references.citation: Nature. 2002 Jun 27;417(6892):949-54
references.pmid: 12068308
references.citation: Pigment Cell Res. 2003 Jun;16(3):287-96
references.pmid: 12753403
references.citation: Cancer. 2010 Nov 1;116(21):4902-13
references.pmid: 20629085
references.citation: J Clin Oncol. 2011 Jul 20;29(21):2904-9
references.pmid: 21690468
references.citation: J Exp Med. 1995 Aug 1;182(2):459-65
references.pmid: 7543139
references.citation: Ann Oncol. 2013 Jun;24(6):1691-7
references.pmid: 23406731
references.citation: Cancer Res. 2004 Oct 1;64(19):7002-10
references.pmid: 15466193
references.citation: Ann Oncol. 2012 Feb;23(2):531-6
references.pmid: 21527587
references.citation: Mol Cancer Ther. 2003 Aug;2(8):753-63
references.pmid: 12939465
references.citation: Nat Rev Drug Discov. 2006 Aug;5(8):671-88
references.pmid: 16883305
references.citation: Nature. 2010 Dec 16;468(7326):968-72
references.pmid: 21107320
references.citation: Clin Cancer Res. 2009 Dec 1;15(23):7412-20
references.pmid: 19934295
references.citation: Cancer. 1998 Aug 15;83(4):797-805
references.pmid: 9708948
references.citation: J Biol Chem. 1996 Dec 13;271(50):31824-30
references.pmid: 8943224
references.citation: Cancer Res. 2011 Apr 1;71(7):2750-60
references.pmid: 21317224
references.citation: J Clin Oncol. 2012 Jan 20;30(3):316-21
references.pmid: 22067401
references.citation: Nat Med. 2002 Aug;8(8):793-800
references.pmid: 12091876
references.citation: Clin Cancer Res. 2011 Dec 1;17(23):7451-61
references.pmid: 21976540
references.citation: Science. 1995 Nov 10;270(5238):932-3
references.pmid: 7481795
references.citation: Mol Cancer Ther. 2012 Apr;11(4):909-20
references.pmid: 22389471
references.citation: Cytokine. 2000 Jun;12(6):547-54
references.pmid: 10843728
references.citation: J Invest Dermatol. 2009 Jun;129(6):1500-15
references.pmid: 19078992
references.citation: N Engl J Med. 2013 Jul 11;369(2):122-33
references.pmid: 23724867
references.citation: Br J Cancer. 2010 Jun 8;102(12):1724-30
references.pmid: 20531415
references.citation: Cancer. 2010 Apr 1;116(7):1757-66
references.pmid: 20143437
references.citation: N Engl J Med. 2011 Jun 30;364(26):2517-26
references.pmid: 21639810
references.citation: Nat Med. 2012 Oct;18(10):1503-10
references.pmid: 22983396
references.citation: Br J Cancer. 2005 Apr 25;92(8):1398-405
references.pmid: 15846297
references.citation: J Clin Oncol. 2013 Feb 1;31(4):499-506
references.pmid: 23248252
references.citation: J Clin Oncol. 2008 Apr 20;26(12):2046-51
references.pmid: 18421059
references.citation: Cancer. 2005 Sep 1;104(5):1045-8
references.pmid: 16007689
references.citation: Lancet Oncol. 2013 Mar;14(3):249-56
references.pmid: 23414587
references.citation: Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):4015-20
references.pmid: 23431193
references.citation: Lancet Oncol. 2012 Aug;13(8):782-9
references.pmid: 22805292
references.citation: Cancer. 2011 May 15;117(10):2202-8
references.pmid: 21523734
references.citation: Mol Cancer Ther. 2009 Aug;8(8):2079-85
references.pmid: 19671763
references.citation: Clin Cancer Res. 2005 Jul 15;11(14):5153-7
references.pmid: 16033830
references.citation: Cancer. 2009 Jan 1;115(1):119-27
references.pmid: 19090009
references.citation: Nat Commun. 2012 Mar 06;3:724
references.pmid: 22395615
references.citation: J Clin Oncol. 2013 May 10;31(14):1767-74
references.pmid: 23569304
references.citation: JAMA. 2011 Jun 8;305(22):2327-34
references.pmid: 21642685
references.citation: N Engl J Med. 2012 Jan 19;366(3):207-15
references.pmid: 22256804
references.citation: Melanoma Res. 2009 Oct;19(5):275-82
references.pmid: 19633580
references.citation: N Engl J Med. 2012 Nov;367(18):1694-703
references.pmid: 23020132
references.citation: PLoS One. 2011;6(12):e28973
references.pmid: 22194965
references.citation: Lancet. 2012 Jul 28;380(9839):358-65
references.pmid: 22735384
references.citation: N Engl J Med. 2012 Jun 28;366(26):2517-9
references.pmid: 22658126
references.citation: Am J Clin Oncol. 2014 Aug;37(4):369-76
references.pmid: 23357973
references.citation: N Engl J Med. 2013 Jul 11;369(2):134-44
references.pmid: 23724846
references.citation: CA Cancer J Clin. 2013 Jan;63(1):11-30
references.pmid: 23335087
references.citation: Clin Cancer Res. 2011 Mar 1;17(5):989-1000
references.pmid: 21245089
references.citation: Invest New Drugs. 2012 Oct;30(5):2008-14
references.pmid: 22068222